Protein Kinase CK-1 Inhibitors As New Potential Drugs for Amyotrophic Lateral Sclerosis
Irene G. Salado(Instituto de Química Médica), Daniel I. Pérez(Cedars-Sinai Medical Center), Magalie Lecourtois(Inserm), Laëtitia Miguel(Inserm), Murilo Lamim Bello(Universidade Federal do Rio de Janeiro), Carmen Gil(Instituto de Salud Carlos III), Nicole F. Liachko(University of Washington), Brian C. Kraemer(University of Washington), Concepción Pérez(Instituto de Química Médica), Miriam Redondo(Instituto de Química Médica), Ana Martı́nez(Consejo Superior de Investigaciones Científicas)
Cited by 122
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293